Welcome

Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated May 13, 2021) (Updated May 10, 2021)
Stock Information
NASDAQNVAX
NASDAQNVAX
Recent News
Jul 6, 2021
Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results...

Jun 30, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a...

Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021

The participation of volunteers in clinical trials is critical to medical research, and Novavax is grateful to those who stepped forward to advance COVID-19 vaccine development to help create a...

View All Press Releases